416 related articles for article (PubMed ID: 34496081)
1. Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study.
Poewe W; Stocchi F; Arkadir D; Ebersbach G; Ellenbogen AL; Giladi N; Isaacson SH; Kieburtz K; LeWitt P; Olanow CW; Simuni T; Thomas A; Zlotogorski A; Adar L; Case R; Oren S; Fuchs Orenbach S; Rosenfeld O; Sasson N; Yardeni T; Espay AJ;
Mov Disord; 2021 Nov; 36(11):2687-2692. PubMed ID: 34496081
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.
Espay AJ; Stocchi F; Pahwa R; Albanese A; Ellenbogen A; Ferreira JJ; Giladi N; Gurevich T; Hassin-Baer S; Hernandez-Vara J; Isaacson SH; Kieburtz K; LeWitt PA; Lopez-Manzanares L; Olanow CW; Poewe W; Sarva H; Yardeni T; Adar L; Salin L; Lopes N; Sasson N; Case R; Rascol O;
Lancet Neurol; 2024 May; 23(5):465-476. PubMed ID: 38499015
[TBL] [Abstract][Full Text] [Related]
3. Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study.
Olanow CW; Espay AJ; Stocchi F; Ellenbogen AL; Leinonen M; Adar L; Case RJ; Orenbach SF; Yardeni T; Oren S; Poewe W;
J Parkinsons Dis; 2021; 11(1):177-186. PubMed ID: 33164945
[TBL] [Abstract][Full Text] [Related]
4. ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.
Giladi N; Gurevich T; Djaldetti R; Adar L; Case R; Leibman-Barak S; Sasson N; Caraco Y
Parkinsonism Relat Disord; 2021 Oct; 91():139-145. PubMed ID: 34619438
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
Fernandez HH; Boyd JT; Fung VSC; Lew MF; Rodriguez RL; Slevin JT; Standaert DG; Zadikoff C; Vanagunas AD; Chatamra K; Eaton S; Facheris MF; Hall C; Robieson WZ; Benesh J; Espay AJ
Mov Disord; 2018 Jul; 33(6):928-936. PubMed ID: 29570853
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
Soileau MJ; Aldred J; Budur K; Fisseha N; Fung VS; Jeong A; Kimber TE; Klos K; Litvan I; O'Neill D; Robieson WZ; Spindler MA; Standaert DG; Talapala S; Vaou EO; Zheng H; Facheris MF; Hauser RA
Lancet Neurol; 2022 Dec; 21(12):1099-1109. PubMed ID: 36402160
[TBL] [Abstract][Full Text] [Related]
7. Continuous subcutaneous levodopa-carbidopa for the treatment of advanced Parkinson's disease: is it an improvement on other delivery?
Doggrell SA
Expert Opin Drug Deliv; 2023; 20(9):1189-1199. PubMed ID: 37634938
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson's disease: A large single-center study.
Blaise AS; Baille G; Carrière N; Devos D; Dujardin K; Grolez G; Kreisler A; Kyheng M; Moreau C; Mutez E; Seguy D; Defebvre L
Rev Neurol (Paris); 2020 May; 176(4):268-276. PubMed ID: 31668287
[TBL] [Abstract][Full Text] [Related]
9. Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials.
Lang AE; Rodriguez RL; Boyd JT; Chouinard S; Zadikoff C; Espay AJ; Slevin JT; Fernandez HH; Lew MF; Stein DA; Odin P; Fung VS; Klostermann F; Fasano A; Draganov PV; Schmulewitz N; Robieson WZ; Eaton S; Chatamra K; Benesh JA; Dubow J
Mov Disord; 2016 Apr; 31(4):538-46. PubMed ID: 26695437
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program.
LeWitt PA; Stocchi F; Arkadir D; Caraco Y; Adar L; Perlstein I; Case R; Giladi N
Front Neurol; 2022; 13():1036068. PubMed ID: 36438968
[TBL] [Abstract][Full Text] [Related]
11. Levodopa/carbidopa intestinal gel infusion and weight loss in Parkinson's disease.
Fabbri M; Zibetti M; Beccaria L; Merola A; Romagnolo A; Montanaro E; Ferreira JJ; Palermo S; Lopiano L
Eur J Neurol; 2019 Mar; 26(3):490-496. PubMed ID: 30347489
[TBL] [Abstract][Full Text] [Related]
12. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
Antonini A; Fung VS; Boyd JT; Slevin JT; Hall C; Chatamra K; Eaton S; Benesh JA
Mov Disord; 2016 Apr; 31(4):530-7. PubMed ID: 26817533
[TBL] [Abstract][Full Text] [Related]
13. Complex dyskinesias in Parkinson patients on levodopa/carbidopa intestinal gel.
Marano M; Naranian T; di Biase L; Di Santo A; Poon YY; Arca R; Cossu G; Marano P; Di Lazzaro V; Fasano A
Parkinsonism Relat Disord; 2019 Dec; 69():140-146. PubMed ID: 31759188
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE-PD Open-Label Extension Study.
Espay AJ; Hauser RA; Dhall R; Thakkar S; Cloud L; Zeitlin L; Banisadr G; Fisher S; Visser H
Mov Disord; 2024 Feb; 39(2):428-432. PubMed ID: 38111267
[TBL] [Abstract][Full Text] [Related]
15. Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.
Poewe W; Bergmann L; Kukreja P; Robieson WZ; Antonini A
J Parkinsons Dis; 2019; 9(3):531-541. PubMed ID: 31282424
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.
Nyholm D; Odin P; Johansson A; Chatamra K; Locke C; Dutta S; Othman AA
AAPS J; 2013 Apr; 15(2):316-23. PubMed ID: 23229334
[TBL] [Abstract][Full Text] [Related]
17. [Levodopa-carbidopa intestinal gel in the treatment of patients with Parkinson disease: results of a 12-month open study].
Skoromets AA; Odinak MM; Yakupov EZ; Litvinenko IV; Zalyalova ZA; Timofeeva AA; Kirtaev SY; Bogdanov RR; Agafina AS; Chatamra K; Robieson W; Benesh J; Latypova GR; Ershova MV; Illarioshkin SN
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2):22-31. PubMed ID: 28374689
[TBL] [Abstract][Full Text] [Related]
18. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
19. Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.
Freire-Alvarez E; Kurča E; Lopez Manzanares L; Pekkonen E; Spanaki C; Vanni P; Liu Y; Sánchez-Soliño O; Barbato LM
Mov Disord; 2021 Nov; 36(11):2615-2623. PubMed ID: 34236101
[TBL] [Abstract][Full Text] [Related]
20. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M
Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
